FDA opens doors for digital tools to facilitate siteless trials, find new endpoints

In its latest steps to make clinical trials more representative of the real world, FDA plans to release draft guidance related to the implementation of siteless trials and the incorporation of new digital tools. The agency is also increasing its capacity to use machine learning and AI to identify

Read the full 494 word article

User Sign In